Inventor · disambiguated record
Thierry Boon-Falleur
Also filed as: BOON-FALLEUR THIERRY · BOON-FALLEUR THIERRY R
143 granted patents·15 pending applications·2,061 citations·filing 1993–2012
99Inventor score
Files withLUDWIG INST CANCER RES131BERINSTEIN NEIL2DEMOTTE NATHALIE2INST NAT SANTE RECH MED2LUDWIG INST FOR CANCER RES LTD2
Top patents by PatentIndex Score
158 records- 0194US7311914B2MAGE-A4 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted Dec 25, 2007·67 cites·11 claims
- 0294US5830753AIsolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.LUDWIG INST CANCER RES·Filed 1994·Granted Nov 3, 1998·82 cites·14 claims
- 0391US5571711AIsolated nucleic acid molecules coding for BAGE tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1993·Granted Nov 5, 1996·69 cites·11 claims
- 0490US5620886AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1993·Granted Apr 15, 1997·75 cites·13 claims
- 0590US5612201AIsolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursorLUDWIG INST CANCER RES·Filed 1994·Granted Mar 18, 1997·127 cites·3 claims
- 0689US5648226AIsolated peptides derived from tumor rejection antigens, and their useLUDWIG INST CANCER RES·Filed 1995·Granted Jul 15, 1997·72 cites·6 claims
- 0788US7049413B2MAGE-A3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 2001·Granted May 23, 2006·11 cites·19 claims
- 0886US8951747B2Method for modulating activity of T lymphocytesDEMOTTE NATHALIE·Filed 2012·Granted Feb 10, 2015·7 cites·14 claims
- 0986US6291430B1Mage-3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 1998·Granted Sep 18, 2001·48 cites·15 claims
- 1086US6130052ALeukemia associated genesLUDWIG INST CANCER RES·Filed 1998·Granted Oct 10, 2000·89 cites·8 claims
- 1185US6303756B1Tumor associated nucleic acids and uses thereforLUDWIG INST CANCER RES·Filed 2000·Granted Oct 16, 2001·10 cites·18 claims
- 1285US5965535AMage-3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 1997·Granted Oct 12, 1999·51 cites·11 claims
- 1385US5683886ATumor rejection antigens which correspond to amino acid sequences in tumor rejection antigen precursor bage, and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Nov 4, 1997·51 cites·6 claims
- 1483US6426217B1MAGE-3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 2000·Granted Jul 30, 2002·17 cites·16 claims
- 1582US5939526AIsolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Aug 17, 1999·55 cites·3 claims
- 1681US7495074B2Isolated proteins MAGE-4 and MAGE-41LUDWIG INST CANCER RES·Filed 2005·Granted Feb 24, 2009·1 cites·8 claims
- 1781US6022692AMethod for screening for possible presence of cancerLUDWIG INST CANCER RES·Filed 1998·Granted Feb 8, 2000·38 cites·7 claims
- 1880US6235525B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereofLUDWIG INST CANCER RES·Filed 1993·Granted May 22, 2001·27 cites·10 claims
- 1979US6669946B2Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of human leukocyte antigen tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 2001·Granted Dec 30, 2003·5 cites·1 claims
- 2079US5585461AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Dec 17, 1996·39 cites·4 claims
- 2179US5487974AMethod for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cellsLUDWIG INST CANCER RES·Filed 1993·Granted Jan 30, 1996·59 cites·6 claims
- 2278US5610013AMethod for diagnosing a disorder by determining expression of gage tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1994·Granted Mar 11, 1997·40 cites·37 claims
- 2378US5462871AIsolated nucleic acid molecules which encode MAGE derived nonapeptidesLUDWIG INST CANCER RES·Filed 1993·Granted Oct 31, 1995·52 cites·16 claims
- 2477US7371845B2MAGE-A3 peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 2006·Granted May 13, 2008·2 cites·20 claims
- 2577US7348007B2Mage C2 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2005·Granted Mar 25, 2008·1 cites·3 claims
- 2677US5587289AIsolated nucleic acid molecules which are members of the MAGE-Xp family and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Dec 24, 1996·28 cites·12 claims
- 2777US5554506AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Sep 10, 1996·31 cites·3 claims
- 2876US7547517B2MAGE-C2 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2003·Granted Jun 16, 2009·3 cites·6 claims
- 2976US7388072B2MAGE peptides presented by HLA class II moleculesLUDWIG INST CANCER RES·Filed 2003·Granted Jun 17, 2008·5 cites·21 claims
- 3076US5591430AIsolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereofLUDWIG INST CANCER RES·Filed 1994·Granted Jan 7, 1997·35 cites·6 claims
- 3175US7851212B2Immunogenic polypeptides encoded by MAGE minigenes and uses thereofSANOFI PASTEUR LTD·Filed 2001·Granted Dec 14, 2010·3 cites·14 claims
- 3275US6939707B2Isolated nucleic acid molecules which encode GAGE genes and uses thereofLUDWIG INST CANCER RES·Filed 2001·Granted Sep 6, 2005·3 cites·9 claims
- 3375US6897288B1Mage-A12 antigenic peptides and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted May 24, 2005·7 cites·16 claims
- 3474US7998483B2Lage-1 tumor associated nucleic acidsLUDWIG INST FOR CANCER RES LTD·Filed 2009·Granted Aug 16, 2011·0 cites·4 claims
- 3574US7199231B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Apr 3, 2007·3 cites·12 claims
- 3674US6946289B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-6 and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Sep 20, 2005·1 cites·6 claims
- 3773US5965381ADelivery of proteins into eukaryotic cells with recombinant yersiniaLUDWIG INST CANCER RES·Filed 1998·Granted Oct 12, 1999·28 cites·64 claims
- 3873US5747271AMethod for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individualsLUDWIG INST CANCER RES·Filed 1996·Granted May 5, 1998·39 cites·2 claims
- 3973US5554724AIsolated tumor rejection antigen precursor MAGE-2 derived peptides, and uses thereofUNIV LEIDEN·Filed 1994·Granted Sep 10, 1996·36 cites·4 claims
- 4072US6552180B1Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-2 and uses thereofLUDWIG INST CANCER RES·Filed 2000·Granted Apr 22, 2003·1 cites·25 claims
- 4172US5695994AIsolated cytolytic T cells specific for complexes of MAGE related peptides and HLA moleculesLUDWIG INST CANCER RES·Filed 1995·Granted Dec 9, 1997·20 cites·6 claims
- 4271US5821122AIsolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Oct 13, 1998·17 cites·16 claims
- 4370US6682731B1Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 moleculesLUDWIG INST CANCER RES·Filed 2000·Granted Jan 27, 2004·3 cites·2 claims
- 4470US6407063B1Tumor antigens and CTL clones isolated by a novel procedureLUDWIG INST CANCER RES·Filed 1998·Granted Jun 18, 2002·27 cites·8 claims
- 4570US6025474AIsolated nucleic acid molecules coding for tumor rejection antigen precursor mage-3 and uses thereofLUDWIG INST CANCER RES·Filed 1997·Granted Feb 15, 2000·21 cites·2 claims
- 4670US2010009437A1Isolated proteins MAGE-4 and MAGE-41GAUGLER BEATRICE·Filed 2009·Application pending·0 cites
- 4769US8143011B2MAGE-C2 antigenic peptides and uses thereofMA WENBIN·Filed 2011·Granted Mar 27, 2012·1 cites·6 claims
- 4869US6201111B1Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursorsLUDWIG INST CANCER RES·Filed 1999·Granted Mar 13, 2001·15 cites·1 claims
- 4969US6017705AIsolated nucleic acid molecules which are members of the MAGE-B family and uses thereofLUDWIG INST CANCER RES·Filed 1997·Granted Jan 25, 2000·15 cites·8 claims
- 5069US5856091AIsolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2LUDWIG INST CANCER RES·Filed 1995·Granted Jan 5, 1999·16 cites·21 claims
Showing the top 50 of 158 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Thierry Boon-Falleur files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →